Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.9816
-0.0784-7.40%
Post-market: 1.000.0184+1.87%16:10 EDT
Volume:99.34K
Turnover:100.76K
Market Cap:1.46M
PE:-0.01
High:1.05
Open:1.00
Low:0.9803
Close:1.06
52wk High:524.00
52wk Low:0.9199
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.03
T/O Rate:6.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-114.61%
ROA:-51.35%
PB:0.13
PE(LYR):0.00

Loading ...

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-based Neuroplastogen Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Posts Update on Cmnd-100 First-in-human Trial Webinar Insights

Reuters
·
Jul 13

Clearmind Medicine submits response to HHS request for information

TIPRANKS
·
Jul 10

Clearmind Medicine Responds to the U.S. Administration’s Rfi for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

THOMSON REUTERS
·
Jul 10

Clearmind Reports Successful Formulation Study for Intranasal MEAI Delivery in Alcohol Use Disorder Program

Reuters
·
Jul 08

Clearmind Medicine Issues Press Release Update

Reuters
·
Jul 07

Clearmind Medicine Wins New US Patent for Binge Behavior Regulators

Reuters
·
Jun 29

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 22

Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder

THOMSON REUTERS
·
Jun 22

Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA‑Regulated Phase I/Ii Trial

THOMSON REUTERS
·
Jun 22

HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares

Reuters
·
Jun 19

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

TIPRANKS
·
Jun 18

Clearmind Medicine wins US patent for MEAI-based binge behavior regulators

Reuters
·
Jun 18

HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56

Reuters
·
Jun 18

HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72

Reuters
·
Jun 16

BRIEF-Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical Trial

Reuters
·
Jun 16

Clearmind Medicine Completes Dosing in First 4 Cohorts of Phase I/II Alcohol Use Disorder Trial

MT Newswires Live
·
Jun 16

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 16

Clearmind Medicine Completes Dosing for Part a of Its of FDA-Regulated Phase I/Ii Clinical Trial

THOMSON REUTERS
·
Jun 16

Clearmind Medicine says HRT Financial files initial beneficial ownership statement

Reuters
·
Jun 13